These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37775712)

  • 1. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.
    De Nicola L; Ferraro PM; Montagnani A; Pontremoli R; Dentali F; Sesti G
    Intern Emerg Med; 2024 Mar; 19(2):295-306. PubMed ID: 37775712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
    Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
    Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
    Jiménez-Marrero S; Cainzos-Achirica M; Monterde D; Vela E; Enjuanes C; Yun S; Garay A; Moliner P; Corbella M; Jovells-Vaqué S; Alcoberro L; Pons-Riverola A; Ramos-Polo R; Morillas H; Gómez-Hospital JA; Comin-Colet J
    Eur J Intern Med; 2024 Jul; 125():89-97. PubMed ID: 38548513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
    Mahmud HA; Palmer BF
    Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
    Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
    Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
    Morales E; Cravedi P; Manrique J
    Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
    Gregg LP; Navaneethan SD
    Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
    Pitt B; Garza D
    Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
    J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
    Dong L; Xu W; Deng Y; Tan J; Qin W
    Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
    Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
    Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
    Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
    Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.